Raw Data for the article: Transjugular Intrahepatic Portosystemic Shunt: A Single-Centre Mid-term Experience Using the Viatorr Controlled-Expansion Stent

Authors reported a high incidence of hepatic encephalopathy (HE) using the Viatorr Controlled Expansion stent (VCX) (Gore, Flagstaff AZ) in a cohort of 33 patients underwent transjugular intrahepatic portosystemic shunt (TIPS) creation. In detail 6 and 12 month overall HE rate was 53% and 61%. Those results are different as compared to our preliminary experience, with the same stent, in which the overall HE rate was 22% in a cohort of 75 patients and with a mean follow up of 5.8 months.